MYOM2 and neoplasm: More detailed biophysicaland structural studies are required to understand how cetuximab-EGFRor cetuximab-protein M binding is different from that of other antibodies.In vitro models of the tumor microenvironment could be used to furthervalidate the concept of using protein M-8his to confer pH sensitivityto antibody-based imaging and therapeutics.